Q3 2021 Investor Relations Results

Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 2 Oncology Code ABL001 Name asciminib BYL719 alpelisib BLZ945 BLZ945 DRB436 Tafinlar® + MekinistⓇ TabrectaⓇ INC280 INC424 Jakavi® LXH254 LXH254 MBG453 sabatolimab NIR178 NIS793 NIR178, spartalizumab NIS793 PDR001 spartalizumab PKC412 Rydapte SEG101 AdakveoⓇ Mechanism BCR-ABL inhibitor PI3Ka inhibitor CSF-1R inhibitor BRAF inhibitor + MEK inhibitor Met inhibitor JAK1/2 inhibitor CRAF inhibitor TIM3 antagonist Ad2AR inhibitor, PD1 inhibitor TGFB1 inhibitor PD1 inhibitor Multi-targeted kinase inhibitor P-selectin inhibitor Indication(s) Chronic myeloid leukemia, 2L, pediatrics PIK3CA-related overgrowth spectrum Solid tumors HGG/LGG, pediatrics Non-small cell lung cancer (Combo) Myelofibrosis (combo) Melanoma (combo) Unfit acute myeloid leukaemia Cancers Colorectal cancer (Combos) Metastatic melanoma (combo) Acute myeloid leukemia, pediatrics Sickle cell anaemia with crisis, pediatrics Immunology, Hepatology, Dermatology Code Name ADPT02 ADPT02 Mechanism References Innovation: Clinical trials 24 lead indications Ophthalmology Name Code CPK850 CPK850 LKA651 LKA651 SAF312 libvatrep UNR844 UNR844 Respiratory & Allergy Mechanism RLBP1 AAV EPO inhibitor TRPV1 antagonist Reduction of disulfide bonds Indication(s) Retinitis pigmentosa Diabetic retinopathy Chronic ocular surface pain Presbyopia Acute GVHD, pediatrics Chronic GVHD, pediatrics Code CMK389 CSJ117 Name CMK389 Mechanism IL-18 inhibitor CSJ117 TSLP inhibitor QBW251 icenticaftor QMF149 AtecturaⓇ CFTR potentiator Combo Indication(s) Non-alcoholic steatohepatitis (Combos) AIN457 Cosentyx® IL17A inhibitor Lichen planus CFZ533 iscalimab CD40 inhibitor Sjögren's Liver Tx Hidradenitis CMK389 CMK389 DFV890 DFV890 IL-18 inhibitor Atopic dermatitis NLRP3 inhibitor Osteoarthritis LJN452 tropifexor +licogliflozin LNA043 LNA043 LOU064 remibrutinib FXR agonist Familial cold auto-inflammatory syndrome Non-alcoholic steatohepatitis (Combos) ANGPTL3 agonist BTK inhibitor Knee osteoarthritis Sjögren's Osteoarthritis (combos) LRX712 LRX712 - Osteoarthritis LYS006 LYS006 Anti-inflammatory MAS825 MAS825 VAY736 TIM3 inhibitor ianalumab Acne Colitis ulcerative Hidradenitis NLRC4-GOF indications BAFF-R inhibitor Systemic lupus erythematosus Sjögren's Autoimmune hepatitis 1. Clinical hold lifted 54 Investor Relations | Q3 2021 Results Cardiovascular, Renal, Metabolism Code Name CFZ533 iscalimab HSY244 HSY244 LNP023 iptacopan Neuroscience Code Name BLZ945 BLZ945 MIJ821 MIJ821 Global Health Mechanism CD40 inhibitor CFB inhibitor Lead indication Indication(s) Pulmonary sarcoidosis Asthma Bronchiectasis Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Asthma, pediatrics Indication(s) Lupus nephritis Type 1 diabetes mellitus Atrial fibrillation Membranous nephropathy Mechanism CSF-1R inhibitor NR2B negative allosteric modulator Indication(s) Amyotrophic lateral sclerosis Depression Code KAE609 KAF156 Name cipargamin ganaplacide Mechanism PfATP4 inhibitor Indication(s) Malaria, severe Malaria, uncomplicated Malaria, uncomplicated LXE408 LXE408 Proteasome inhibitor Visceral leishmaniasis 1 NOVARTIS | Reimagining Medicine

View entire presentation